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ABSTRACT
Background. Despite evidence of different malignant
potentials, postoperative follow-up assessment is similar
for G1 and G2 pancreatic neuroendocrine tumors (pan-
NETs) and adjuvant treatment currently is not indicated.
This study investigated the role of Ki67 with regard to
recurrence and survival after curative resection of panNET.
Methods. Patients with resected non-functioning panNET
diagnosed between 1992 and 2016 from three institutions
were retrospectively analyzed. Patients who had G1 or G2
tumor without distant metastases or hereditary syndromes
were included in the study. The patients were re-catego-
rized into Ki67 0–5 and Ki67 6–20%. Cox regression
analysis with log-rank testing for recurrence and survival
was performed.
Results. The study enrolled 241 patients (86%) with Ki67
0–5% and 39 patients (14%) with Ki67 6–20%. Recurrence
was seen in 34 patients (14%) with Ki67 0–5% after a
median period of 34 months and in 16 patients (41%) with
Ki67 6–20% after a median period of 16 months
(p\ 0.001). The 5-year recurrence-free and 10-year dis-
ease-specific survival periods were respectively 90 and
91% for Ki67 0–5% and respectively 55 and 26% for Ki67
6–20% (p\ 0.001). The overall survival period after
recurrence was 44.9 months, which was comparable
between the two groups (p = 0.283). In addition to a Ki67
rate higher than 5%, tumor larger than 4 cm and lymph
node metastases were independently associated with
recurrence.
Conclusions. Patients at high risk for recurrence after
curative resection of G1 or G2 panNET can be identified by
a Ki67 rate higher than 5%. These patients should be more
closely monitored postoperatively to detect recurrence
early and might benefit from adjuvant treatment. A clear
postoperative follow-up regimen is proposed.
One of the concerns for patients with pancreatic neu-
roendocrine tumors (panNETs) is the accurate prediction of
clinical outcome. Tumor stage and grade have proved to be
useful in estimating disease course and have been con-
firmed repeatedly in valuable studies.1–6 Despite this,
follow-up assessment is the same for all patients who have
undergone curative resection of panNET. Neither surveil-
lance protocols nor adjuvant treatment options based on
expected recurrence rates are available, although the
recurrence rate is reported to be 17% after resection of
well-differentiated panNET, with considerable conse-
quences for survival.7
The 2010 tumor grade classification of the World Health
Organization (WHO) divides panNET into three prognostic
groups based on the proliferation index assessed through
the expression of the nuclear antigen Ki67, with Ki67\
3% classified as low-grade panNET (G1), Ki67 3–20%
classified as intermediate-grade panNET (G2), and
Ki67[ 20% classified as high-grade neuroendocrine car-
cinoma (NEC) (G3).8–11
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Multiple studies have shown a good correlation between
the Ki67 index and tumor size, angioinvasion, and biologic
behavior of neuroendocrine tumors.12–14 However,
heterogeneity of panNET is increasingly described, and the
wide range of the Ki67 distribution in the grading systems
is under debate.15–17 Therefore, WHO proposed an updated
classification system for panNET this year, in which high-
grade tumors with Ki67[ 20% are subdivided into well-
differentiated G3 NET and poorly differentiated G3
NEC.18 Although clear upper or lower limits for G3 NET
and G3 NEC are not provided, differences in genetic basis
and the course of disease are suggested.19–21 Similar
assumptions also are apparent for tumors with Ki67\
20%. A Ki67 cutoff of 10% is used to select patients
suitable for liver transplantation according to the Milan
criteria, comparable with the inclusion criteria of the
Clarinet study and of many oncologists generally when
choosing a systemic treatment.22,23
For non-metastasized patients, the latest European
Neuroendocrine Tumor Society (ENETS) guidelines also
discriminate between ‘‘low-G2’’ and ‘‘high-G2’’ panNET
without providing cutoff values, suggesting different
treatment responses within this patient population.1 Fur-
thermore, several studies describe a higher discriminating
capacity when G1 and G2 panNET are divided by a Ki67
cutoff of 5% instead of 3% to predict disease
progression.5,24,25
After curative surgery of panNET, follow-up assessment
is focused on early detection of recurrence. The use of the
Ki67 proliferation index to guide postoperative manage-
ment has not been described previously.7,26,27 Based on the
capacity of Ki67 to predict disease outcome in general, it is
likely that the proliferation index of surgically treated
panNET could also be predictive in estimating the risk for
the development of recurrence. Therefore, we hypothesized
that panNET with Ki67\ 20% indicates a heterogeneous
group of tumors with a different postoperative disease
course and aimed to investigate the role of Ki67 in pre-
dicting recurrence and survival after curative resection.
METHODS
The study enrolled patients who underwent a curative
resection of a non-functioning panNET with Ki67\ 20%
between 1992 and 2016 from the following three academic
centers: The Academic Medical Center Amsterdam and
The Erasmus University Rotterdam in the Netherlands
(both ENETS Centers of Excellence) and the Ospedale San
Raffaele in Milan, Italy. The data for 211 patients (75%)
also have been presented in a previous study of this group.7
All the patients were free of distant metastatic disease at
diagnosis and not associated with a genetic predisposition
for the development of panNET. Pathology reports were
reviewed for the diagnosis of panNET, and patients were
included in the study if panNET was histologically proven.
All patients with (unresectable) locally advanced or distant
metastatic disease, successfully treated or not, were
excluded from the study.
The functional status of the tumors was based on the
clinical presentation of symptoms associated with hor-
monal overproduction. The Ki67 proliferation index was
retrieved from pathology reports. Tumor tissue of patients
with a diagnosis before 2010 or with pathology reports
containing insufficient information on the Ki67 index
(n = 24) were reassessed with an emphasis on Ki67 by
experienced pathologists.
For all the patients, visual assessment (‘‘eyeballing’’)
was used to assess Ki67, and histologic grade was based on
the WHO classification of 2010.28 Classification according
to the Royal College of Pathologists was used to assess
resection margins.29 Depending on the tumor location,
pancreaticoduodenectomy, distal pancreatectomy, or total
pancreatectomy was performed. Central pancreatectomy or
enucleation was performed for patients with a small pan-
NET far enough from the pancreatic duct.
Lymphadenectomy was not routinely performed with
enucleation.
The patients were categorized into groups based on the
Ki67 proliferation index of the tumor. Because pathologists
frequently did not report an exact number to indicate Ki67,
but rather provided a range for the proliferation rate,
groups were initially defined by the most commonly used
cutoffs provided in the pathology reports as follows: G1
(Ki67 0–2%), low G2 (Ki67 3–5%), mid-G2 (Ki67
6–10%), and high G2 (Ki67 11–20%). Because early
Kaplan–Meier analysis (Fig. 1a) showed similar results for
patients with G1 and low G2, as well as for patients with
mid-G2 and high G2, and because the cutoff of 5% also
was supported by Cox proportional hazard regression
(Table 1), the patients were re-categorized into two groups:
Ki67 0–5 and Ki67 6–20% (Fig. 1b).
Follow-up assessment after resection consisted of
physical exams, laboratory tests, and radiologic imaging.
The frequency of hospital visits was at least every
6 months for the first 2 years and yearly thereafter. Follow-
up time was defined as the time to the last known date the
patient was alive or the time until death. Recurrence was
defined as local recurrence in the pancreas, a new location
in lymph nodes, or the development of distant metastases.
All recurrences were identified through radiologic imaging.
Statistical analyses were performed using IBM SPSS
Statistics 23 (IBM Corp., Armonk, NY). On the basis of the
distribution, the data were described using mean and
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standard deviation (SD) or using median and interquartile
range (IQR). For categorical data, the number and pro-
portion (%) were displayed. Differences between patient
and tumor characteristics were investigated using a Chi-
square statistic for categorical values and a Mann–Whitney
U test for numeric values.
Kaplan–Meier survival analyses with log-rank testing
were performed to investigate recurrence-free and disease-
specific survival. To identify variables associated with
recurrence within 5 years after surgery, Cox proportional
hazard regression analyses were performed. Receiver-op-
erating-characteristic (ROC) analysis with area-under-
curve (AUC) determination was performed to investigate
the diagnostic ability with regard to recurrence and disease-
specific survival. The results were presented with the
hazard ratio (HR) and the 95% confidence interval (CI).
The discriminative ability of the model was examined by
calculating the Harrel c-statistic with 95%.30 Moreover, we
examined the discrimination of the WHO grade model and
compared the c-statistics of the two models using a z test.
The net reclassification improvement (NRI) analysis was
used to quantify how well our new proposed model
reclassified subjects compared with the current WHO
grading classification.31,32
RESULTS
This study analyzed 280 patients. Patient and tumor
characteristics are presented in Table 2. Left pancreatec-
tomy was performed for 136 patients (49%),
pancreaticoduodenectomy for 80 patients (29%), enucle-
ation for 45 patients (16%), central pancreatectomy for 13
patients (5%) and total pancreatectomy for 5 patients (2%).
Tumors with Ki67 0–5% were seen in 241 patients,
whereas 39 patients had a panNET with Ki67 6–20%. The
patients with Ki67 6–20% more frequently had lymph node
metastases (53 vs 22%; p = 0.0002), perineural invasion
(28 vs 11%; p = 0.0129), vascular invasion (51 vs 20%;
p\ 0.0001), and R1 resection (36 vs 12%; p = 0.0438)
than the patients with Ki67 0–5%.
Recurrence and Survival
Recurrence was experienced by 49 patients (18%), and
the majority (53%) of these recurrences were located in
distant organs. The patients with recurrence more often had
tumors in the pancreatic head (45 vs 36%; p = 0.0174),
tumors larger than 2 cm (86 vs 54%; p\ 0.0001), WHO
2010 grade 2 tumors (47 vs 25% G1; p = 0.0033), R1
resection (26 vs 11%; p = 0.0126), lymph node metastases
(60 vs 19%; p\ 0.0001), perineural invasion (30 vs 10%;
p = 0.0004), and vascular invasion (49 vs 19%;
p = 0.0342) than the patients without recurrence.
Of the 241 patients with Ki67 0–5%, 34 (14%) had a
recurrence. Local recurrence in the pancreas of 12 patients
was observed and recurrence in the regional lymph nodes
of 2 patients. Distant metastases developed in 18 patients.
Of the 39 patients with Ki67 6–20%, 16 (41%) had a
recurrence, with 1 found locally in the pancreas, 2 found in
regional lymph nodes, and 8 found as distant metastases.
Kaplan–Meier analysis showed significantly less recur-
rence within 5 years after surgery for the patients with
Ki67 0–5% than for the patients with Ki67 6–20%
(p\ 0.001; Fig. 1b). The 5-year recurrence-free survival
rate was 90% for the patients with Ki67 0–5 and 55% for
the patients with Ki67 6–20%. Overall, the median time to
recurrence (TTR) was 31.7 months (IQR 10.5–47 months):
34 months (IQR 16–59 months) for the patients with Ki67
0–5% and 16 months (IQR 4.25–23.25 months) for the
patients with Ki67 6–20% (p = 0.005).
The median survival time was 63 months for the
patients with Ki67 0–5% tumors and 45 months for the
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FIG. 1 Recurrence within 5 years after curative resection. A Patients
categorized into four groups based on Ki67. B Patients categorized in
two groups based on Ki67
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patients with Ki67 6–20% tumors (p = 0.017). The 10-year
disease-specific survival was 91% for the patients with
Ki67 0–5% tumors and 26% for the patients with Ki67
6–20% tumors (p\ 0.001, Fig. 2). The median survival
time after recurrence was 44.9 months (IQR
16–68.3 months), which was statistically comparable
between the two groups (p = 0.283).
The ROC analysis for Ki67 showed an AUC of 0.683 for
the prediction of recurrence within 5 years. The highest
sensitivity and specificity were reached at a Ki67 cutoff
value of 5%, with a sensitivity of 37% and a specificity of
87%. An AUC of 0.737 was found for 10-year disease-
specific survival.
The discriminative ability of this Ki67 model showed a
Harrel c-statistic of 0.672 (95% CI 0.591–0.753). The
discrimination of the WHO grading with regard to pre-
dicting recurrence was comparable, with a c-statistic of
0.681 (95% CI 0.602–0.760). This was not statistically
significant (p = 0.781).
Net Reclassification Improvement Analysis
Table 3 presents the results of the NRI analysis. The
additive NRI of the proposed Ki67 cutoff value was 0.866,
indicating that the new cutoff value had good additive
value for the WHO grading classification. The absolute
NRI was 10%, indicating that 10% of patients were cor-
rectly reclassified in our proposed model based on their risk
for the development of recurrence within 5 years. This
effect can best be attributed to the reclassification of
patients with a low risk for the development of recurrence.
Cox Proportional Hazard Analysis
The factors related to recurrence within 5 years after
surgery from the univariable Cox regression analyses were
tumor size greater than 4 cm, WHO tumor grade,
Ki67[ 5%, lymph node metastases, and perineural and
vascular invasion. The independent predictors for recur-
rence were tumor size greater than 4 cm (HR 2.5; 95% CI
TABLE 1 Predictors for
recurrence within 5 years
(n = 280)
Univariate Cox regression Multivariable Cox regression
HR 95% CI p value HR 95% CI p value
Male sex 0.99 0.49–2.00 0.976
Age (years)
\ 40 Ref Ref Ref
41–50 0.72 0.18–2.88 0.639
51–60 0.86 0.23–3.26 0.826
61–70 1.06 0.30–3.74 0.923
[ 70 0.20 0.02–1.95 0.167
Tumor location
Head Ref Ref Ref
Body 0.86 0.36–2.05 0.738
Tail 0.85 0.37–1.97 0.704
Tumor size (mm)
\ 20 Ref Ref Ref
21–40 2.45 0.84–7.16 0.102
[ 41 6.13 2.24–16.75 \0.001 2.27 1.10–4.72 0.027
R1 resection 1.72 0.71–4.19 0.233
WHO tumor grade 0.24 0.12–0.47 \0.001 – – –
Ki67 (%)
0–2 Ref Ref Ref
3–5 1.99 0.72–5.52 0.188
6–10 5.88 2.46–14.05 \0.001
11–20 7.68 2.52–23.42 \0.001
Ki67[ 5% 5.54 2.68–11.43 \0.001 5.21 1.47–18.4 0.010
Positive lymph nodes 4.95 2.32–10.58 \0.001 3.36 1.48–7.61 0.004
Perineural invasion 3.17 1.41–7.17 0.005 – – –
Vascular invasion 3.09 1.50–6.37 0.002 – – –
HR hazard ratio, CI confidence interval, WHO World Health Organization
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1.14–5.40), Ki67[ 5% (HR 3.0; 95% CI 1.34–6.81), and
lymph node metastases (HR 3.3; 95% CI 1.40–7.70)
(Table 1). Tumors larger than 4 cm were seen in 67
patients, 21 (31%) of whom experienced a recurrence. The
absolute NRI of Ki67 compared with size was 6.5%.
Lymph node metastases were present in 65 patients, 27 of
whom experienced recurrence (42%). The absolute NRI of
Ki67 compared with lymph node metastases was 5%.
The 10-year disease-specific survival was associated
with Ki67[ 5% and perineural invasion in the univariate
analysis, but only Ki67[ 5% was independently associ-
ated with 10-year disease specific survival in the
multivariable Cox regression analysis (HR 6.5; 95% CI
1.93–21.79; p = 0.003).
DISCUSSION
We propose a novel categorization of low- and inter-
mediate-grade panNET based on the Ki67 index to predict
recurrence after curative resection. Tumors with Ki67
TABLE 2 Tumor and patient characteristics (n = 280)
n (%)
Male:female 136:144
Median age: years (IQR) 59 (48.8–66)
Median follow-up: months (IQR) 62 (36–84)
Tumor location
Head 105 (38)
Body 81 (29)
Tail 94 (34)
Mean Ki67 (%) 2.8 ± 3.7
0–2 199 (71)
3–5 42 (15)
6–10 28 (10)
11–20 11 (4)
Median tumor size: mm (IQR) 25 (15–40)
\ 20 113 (40)
21–40 100 (36)
[ 40 67 (24)
R0:R1 240:39
Lymph node metastases 65 (23)
Missing (%) 12
Perineural invasion 34 (13)
Missing (%) 9
Vascular invasion 65 (25)
Missing (%) 5
Recurrence 49 (18)
Local 12 (25)
Regional 4 (8)
Distant 26 (53)
Unknown location 7 (14)
Median size: mm (IQR) 40 (25–59)
Mean Ki67 (%) 4.8 ± 5.4
G2a 23/49 (47)
R1 resection 13/49 (27)
Lymph node metastases 27/49 (55)
Perineural invasion 13/49 (27)
Vascular invasion 23/49 (47)
Median time to recurrence: months (IQR) 31.7 (10.5–47)
Median survival after recurrence: months (IQR) 44.9 (16–68.3)
[ 30-day mortality 25 (9)
Disease-related deaths 14 (5)
IQR interquartile range
aAccording to the 2010 World Health Organization (WHO)
classification8
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TABLE 3 Reclassification of patients with and without recurrence
WHO grading model New proposed Ki67 cutoff
Ki67 0–5% Ki67 6–20% Total
Patients with recurrence (n = 49, 17.5%)
Grade 1 26 0 26
Grade 2 7 16 23
Total 33 16 49
Patients without recurrence (n = 231, 82.5%)
Grade 1 173 0 173
Grade 2 35 23 58
Total 208 23 231
Net reclassification of patients with recurrence: 0 - 7 = - 7. Net
reclassification of patients without recurrence: 35 - 0 = 35. Additive
net reclassification improvement (NRI) analysis: ([- 7/
49] 9 100) ? ([35/231] 9 100) = 0.866. Absolute NRI analysis:
([- 7 ? 35]/280) 9 100 = 10%
WHO World Health Organization
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6–20% have a threefold higher risk for the development of
recurrence within 5 years and show significantly shorter
survival than tumors with Ki67 B 5%. With this cutoff
value, a reliable method for stratifying patients into groups
of high and low risk for recurrence after surgery is
presented.
In a previous study, we presented a scoring system to
identify high-risk patients through three predictors for
recurrence.7 The current study contributes to strengthening
of this scoring system. When the criteria for grade 2 tumors
are modified for tumors with Ki67[ 5%, it will be pos-
sible to identify high-risk patients more accurately. The
recurrence score showed a sensitivity of 91% and a
specificity of 62% and is expected to increase with this
revision. Furthermore, patients with Ki67 3–5% (15% of
our cohort) will be downgraded by this modification, lim-
iting unnecessary treatment or monitoring. External
validation of the scoring system currently is being per-
formed and will include this new Ki67 distribution as well.
Postoperative follow-up assessment of patients with
panNET typically consists of hospital visits combined with
laboratory tests and/or radiologic or nuclear imaging. A
clear guideline for postoperative management such as the
frequency of hospital visits, the method for diagnostic
testing, or the duration of follow-up assessment has not
been recommended to date. Combining the presented
results with preexistent literature, we propose a postoper-
ative surveillance protocol based on the risk of recurrence
for patients who have non-metastasized panNET with
K67\ 20% (Table 4). This scheme comprises yearly
consultations with imaging for all patients and additional
half-yearly consultations with clinical assessments and
laboratory tests (chromogranin A) for high risk-patients.
Based on clinical findings and laboratory results, additional
imaging may be obtained.
Ideally, imaging is alternated between radiologic and
somatostatin receptor imaging to achieve the highest
accuracy. Findings have shown that gallium-based nuclear
imaging has the highest sensitivity and specificity for the
detection of panNET and is therefore the preferred nuclear
imaging method.33–36 Radiologic imaging with either
contrast-enhanced computed tomography (CT) or (diffu-
sion weighted) magnetic resonance imaging (MRI) is
advised.37–39 Based on the median time to recurrence, a
follow-up period of 10 years is encouraged because late
recurrences have been described.7 The interval between
assessments can be increased if the disease is stable after
5 years, especially for low-risk patients.
Due to the retrospective nature of this study, it was not
possible to assess exact Ki67 rates for each patient. It is
questionable, however, whether exact rates for each tumor
will be more meaningful in determining postoperative
prognosis. At this writing, exact Ki67 values have limited
clinical relevance because the choice for treatment is often
determined by tumor grade or smaller ranges of Ki67.
Furthermore, the proliferation index of a tumor may have
different prognostic significance in different stages of dis-
ease or treatment. This is already evident, for example, in
determination of systemic treatment options for patients
with disseminated disease. A Ki67 cutoff of 10% often is
used by oncologists, confirming heterogeneity in malignant
potential within one WHO grading group. The treatment of
localized nonfunctioning tumors smaller than 2 cm might
also be influenced by different Ki67 cutoffs, in which the
choice for surgical versus conservative treatment may
change for G2 tumors with higher or lower Ki67 values. In
addition, assessing the exact amount of Ki67-positive cells,
either manually on printed images or determined through
computer software, also can create a false sense of accu-
racy because each method for counting positive cells is
associated with an error margin. Likewise, differences in
practice can lead to intra- and interobserver variability.
Therefore, it might be both more reliable and more feasible
to agree on smaller ranges of Ki67 (e.g.,\ 5, 5–10,
15–20%) rather than exact values, with stratification of
patients into their risk for the development of recurrence.
The current results must be seen in light of their limi-
tations. Data were evaluated retrospectively, and pathology
reports were not standardized at the time of treatment.
Furthermore, the treatment of recurrence was not taken into
account when survival was analyzed. Because survival
after recurrence was comparable between Ki67 0–5 and
TABLE 4 Surveillance protocol after curative resection of pancreatic neuroendocrine tumor (panNET) with Ki76\ 20%
Yearly follow-up Additional follow-up Frequency Duration (years)
Low-risk patientsa Clinical assessment imagingb – Yearly C 5
High-risk patientsa Clinical assessment imagingb Clinical assessment laboratory testsc Every 6 months 10
aRisk stratification either through the newly proposed Ki67 distribution, or more accurately through the modified version of the recurrence score
by Genc¸ et al.7
bAlternating between anatomic and nuclear methods
cChromogranin A
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Ki67 6–20% tumors, we expect the treatment of these
patients to be similar. Nevertheless, results might be
biased, and survival after recurrence might show treatment
results rather than the effect of recurrence itself. In addi-
tion, these results could be interpreted with the assumption
that early detection and treatment of recurrence will result
in survival benefit. However, no studies support this theory,
and prospective clinical trials are necessary to confirm
these hypotheses.
At this writing, the clinical relevance of this study may
be limited except for de-escalation of follow-up regimens
for Ki67 0–5% patients and intensification of follow-up
regimens for patients with Ki67 6–20%. Adjuvant therapy
to prevent recurrence in the future could be a possibility.
However, the vicious circle of nonexistent data, together
with the difficulty of obtaining prospective studies for this
purpose, forms an obstacle to the development of such
treatments. To overcome these issues, a consensus study
has been initiated among European panNET experts to
discuss possibilities for investigating the role of adjuvant
treatment for high-risk patients. The results of this con-
sensus will be published shortly. The current study might
bring us one step closer to achieving this necessary
research by clarifying the selection of patients who should
be eligible for adjuvant treatment.
In conclusion, this study is the largest study to describe
the use of the Ki67 proliferation index to estimate post-
operative recurrence. These results contribute to the
assumption of tumor heterogeneity among patients with a
Ki67\ 20%. Future studies should focus on determining
Ki67 rates, preferably in prospective trials, to propose a
further alteration of the grading system for well-differen-
tiated panNET.
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